These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38772827)

  • 1. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
    Nguyen NC; Anigati EM; Desai NB; Öz OK
    Semin Nucl Med; 2024 Jul; 54(4):488-496. PubMed ID: 38772827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
    Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer.
    Konishi K; Ishiba R; Ikenohira T; Asao T; Hirata M; Ohira K; Komatsu T; Sawada M; Tanahashi Y; Goshima S; Magata Y; Nakamura K
    Ann Nucl Med; 2021 Feb; 35(2):159-166. PubMed ID: 33387279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
    Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
    Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey.
    Jabin Z; Kwon SY; Bom HS; Lin Y; Yang K; Inaki A; Dewi AR; Al-Ibraheem AN; Balooshi BA; San Luis TOL;
    Nucl Med Commun; 2018 Apr; 39(4):283-289. PubMed ID: 29381585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience.
    Wijewardene A; Gild M; Nylén C; Schembri G; Roach P; Hoang J; Aniss A; Glover A; Sywak M; Sidhu S; Learoyd D; Robinson B; Tacon L; Clifton-Bligh R
    Eur Thyroid J; 2021 Jul; 10(5):408-415. PubMed ID: 34540711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
    Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
    Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
    J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
    Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
    Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.